Invasive Pneumococcal Disease Study

Launched by ASSOCIATION CLINIQUE THÉRAPEUTIQUE INFANTILE DU VAL DE MARNE · Dec 7, 2020

Keywords

ClinConnect Summary

The Invasive Pneumococcal Disease Study is a clinical trial aimed at understanding the impact of pneumococcal vaccination on serious infections caused by the bacteria Streptococcus pneumoniae. This study will look at how the vaccine affects invasive pneumococcal disease (IPD), which can lead to severe health issues. Researchers will gather information about patients’ health, the types of pneumococcal bacteria involved, any underlying health conditions, and whether the patients have been vaccinated.

Anyone aged 1 to 6574 who has a confirmed case of pneumococcal infection, indicated by specific tests on blood or other body fluids, may be eligible to participate. If you join the study, you can expect to provide information about your health and vaccination status. It’s important to know that only certain strains of the bacteria will be included in this study, so if your strain isn’t part of the study, you won’t be able to participate. Overall, this research aims to improve our understanding of pneumonia and enhance vaccination strategies for better health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood PCR.
• Exclusion Criteria:
• • Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory